CalciMedica (CALC)

• Market cap: $8.78M
• 1 day: -9.1%
• 5 days: -28.35%
• 1 month: -89.87%
• 3 months: -79.63%
• 6 months: -80.03%
• Year to date: -90.96%
• 1 year: -76.93%
• 5 years: -99.86%
• 10 years: -99.74%
• Sector: Healthcare
• Industry: Biotechnology

About: CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.

Employees: 15